bluebird bio Q1 Sales $18.600M Miss $19.551M Estimate
Portfolio Pulse from Benzinga Newsdesk
bluebird bio (NASDAQ:BLUE) reported Q1 sales of $18.600 million, missing the consensus estimate of $19.551 million by 4.86%, but marking a 681.18% increase from the same period last year.
May 09, 2024 | 11:01 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
bluebird bio reported Q1 sales of $18.600 million, missing estimates by 4.86% but showing significant year-over-year growth.
While BLUE missed the sales estimates, the substantial year-over-year growth indicates strong revenue momentum. The miss is relatively minor and may not significantly impact investor sentiment in the short term, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100